Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Selegiline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 10/20 | 1.00 |
| ▸ | MAOA | P21397 | 7/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.97 |
| ▸ | SNCA | P37840 | 1/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.97 |
| ▸ | PKM | P14618 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Selegiline SCHEMBL41392 | 1.00 | MAOB (1.00) | MAOBMAOAMAPK1KDM4ECYP1A2 | |
| Selegiline SCHEMBL12248117 | 0.98 | MAOB (1.00) | MAOBMAOAMAPK1KDM4ECYP1A2 | |
| Selegiline SCHEMBL22232 | 0.98 | MAOB (1.00) | MAOBMAOAMAPK1KDM4ECYP1A2 | |
| Selegiline SCHEMBL1286950 | 0.98 | MAOB (1.00) | MAOBMAOAMAPK1KDM4ECYP1A2 | |
| Selegiline SCHEMBL5499736 | 0.98 | MAOB (1.00) | MAOBMAOAMAPK1KDM4ECYP1A2 | |
| Selegiline SCHEMBL74753 | 0.98 | MAOB (1.00) | MAOBMAOAMAPK1KDM4ECYP1A2 | |
| Selegiline SCHEMBL15867136 | 0.98 | MAOB (1.00) | MAOBMAOAMAPK1KDM4ECYP1A2 | |
| Selegiline SCHEMBL7105217 | 0.95 | MAOB (0.93) | MAOBMAOAMAPK1KDM4ECYP1A2 | |
| Selegiline SCHEMBL1171497 | 0.95 | MAOB (0.93) | MAOBMAOAMAPK1KDM4ECYP1A2 | |
| Selegiline SCHEMBL4611911 | 0.93 | MAOB (0.90) | MAOBMAOAMAPK1KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 286 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002080855-A2 | METHODS AND COMPOUNDS FOR DECREASING CELL TOXICITY OR DEATH | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2002-10-17 | — | — | WO | claimed |
| US-20260014180-A1 | BIOACTIVES AND THEIR USES | AREPA IP LTD (NZ) | 2026-01-15 | — | — | US | disclosed |
| EP-4618981-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | Remedi, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12390424-B2 | Sulfur (VI) fluoride compounds and methods for the preparation thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-08-19 | — | — | US | disclosed |
| US-12390422-B2 | Transdermal drug delivery patch, drug delivery system and drug delivery | Passport Technologies, Inc. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250248969-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | REMEDI INC (US) | 2025-08-07 | — | — | US | disclosed |
| US-12263155-B2 | Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use | REMEDI, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20250090564-A1 | BIOACTIVES AND THEIR USES | AREPA IP LIMITED (NZ) | 2025-03-20 | — | — | US | disclosed |
| WO-2025048651-A1 | BIOACTIVES AND THEIR USES | AREPA IP LIMITED (NZ) | 2025-03-06 | — | — | WO | disclosed |
| EP-4486354-A1 | BIOACTIVES AND THEIR USES | Arepa IP Limited (NZ) | 2025-01-08 | — | — | EP | disclosed |
| EP-0527835-A1 | DOSAGE FORM TO DELIVER AN ANTIPARKINSON AGENT. | ALZA CORP (US) | 1993-02-24 | — | — | EP | disclosed |
| EP-0294441-B1 | COMPOSITION TO PREVENT SEASICKNESS | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1992-12-02 | — | — | EP | disclosed |
| US-5128145-A | Dosage form for Parkinson's disease, spasticity and muscle spasms | ALZA CORPORATION (US) | 1992-07-07 | — | — | US | disclosed |
| WO-1991016885-A1 | DOSAGE FORM TO DELIVER AN ANTIPARKINSON AGENT | ALZA CORPORATION (US) | 1991-11-14 | — | — | WO | disclosed |
| US-5057321-A | Dosage form comprising drug and maltodextrin | ALZA CORPORATION (US) | 1991-10-15 | — | — | US | disclosed |
| EP-0294441-A1 | COMPOSITION TO PREVENT SEASICKNESS. | CHINOIN GYOGYSZER ES VEGYESZET (HU) | 1988-12-14 | — | — | EP | disclosed |
| WO-1988004552-A1 | COMPOSITION TO PREVENT SEASICKNESS | Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. (HU) | 1988-06-30 | — | — | WO | disclosed |
| EP-0099302-B1 | NEW PROCESS FOR THE PREPARATION OF PROPARGYL AMINES | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1986-10-01 | — | — | EP | disclosed |
| US-4564706-A | Process for the preparation of propargyl amines | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA R.T. (HU) | 1986-01-14 | — | — | US | disclosed |
| EP-0099302-A2 | New process for the preparation of propargyl amines | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1984-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390424-B2 | Sulfur (VI) fluoride compounds and methods for the preparation thereof | GRB2, SCTR, OGFR | MAOB 2996/4885MAOA 3559/4885MAPK1 3615/4885 |
| US-20250090564-A1 | BIOACTIVES AND THEIR USES | MAOA, MAOB, TYR | MAOB 2/4885MAOA 1/4885MAPK1 1267/4885 |
| US-12263155-B2 | Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use | MAOA, MAOB, HTR1A | MAOB 2/4885MAOA 1/4885MAPK1 2299/4885 |
| US-20260014180-A1 | BIOACTIVES AND THEIR USES | MAOB, MAOA, COMT | MAOB 1/4885MAOA 2/4885MAPK1 2399/4885 |
| US-20250248969-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | MAOA, MAOB, HTR1A | MAOB 2/4885MAOA 1/4885MAPK1 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.